https://www.finanznachrichten.de/chart-tool/aktie/abcellera-biologics-inc.htm
ABCELLERA BIOLOGICS Chartanalyse
Chart zur ABCELLERA BIOLOGICS INC Aktie. Alle Charts zu Ihren Aktien.
abcellera biologicschartanalyse
https://www.fool.com/earnings/call-transcripts/2024/02/20/abcellera-biologics-abcl-q4-2023-earnings-call-tra/
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript | The Motley Fool
Feb 21, 2024 - ABCL earnings call for the period ending December 31, 2023.
earnings call transcriptabcellera biologicsq4 2023the motleyabcl
https://www.nasdaq.com/events/abcellera-biologics-inc.-rings-the-closing-bell-in-celebration-of-its-ipo
AbCellera Biologics Inc. Rings the Closing Bell in Celebration of its IPO | Nasdaq
ABOUT THIS EVENT AbCellera Biologics Inc. (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation...
https://www.businesswire.com/news/home/20260401189819/en/AbCellera-to-Report-First-Quarter-2026-Financial-Results-on-May-11-2026
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
first quarter 2026financial resultsabcellerareport
https://www.abcellera.com/
AbCellera
We are advancing differentiated antibody drug programs with first-in-class and best-in-class potential across multiple indications and modalities.
abcellera
https://www.biospace.com/abcellera-closes-105-million-series-b-financing-to-further-advance-world-leading-antibody-drug-discovery-platform
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug...
May 27, 2020 - AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics
https://www.biospace.com/abcellera-and-gilead-forge-infectious-disease-pact
AbCellera and Gilead Forge Infectious Disease Pact - BioSpace
Jun 13, 2019 - AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.
infectious diseaseabcelleragileadforgepact
https://investingnews.com/abcellera-to-present-at-upcoming-investor-conferences-in-march-and-april-2026/
AbCellera to Present at Upcoming Investor Conferences in March and April 2026 | INN
Feb 11, 2026 - AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference,...
march and april 2026
https://www.sofi.com/invest/stock/ABCL/
Buy AbCellera Biologics Stock - ABCL Stock Price, Quote & News | SoFi
See real time price charts for ABCL stock, historical data, and recent news. Buy ABCL stock online with no commission fees.
abcellera biologicsprice quotebuystockabcl
https://investingnews.com/abcellera-appoints-dr-stephen-quake-to-its-board-of-directors/
AbCellera Appoints Dr. Stephen Quake to its Board of Directors | INN
Nov 10, 2025 - AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a...
board of directorsstephen quakeabcelleraappointsdr
https://www.businesswire.com/news/home/20260420968823/en/AbCellera-to-Highlight-Phase-1-Clinical-Data-for-ABCL635-During-Upcoming-First-Quarter-2026-Earnings-Call
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026...
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
https://www.home.saxo/en-sg/markets/stocks/abcl-xnas
AbCellera Biologics Inc. stock | Saxo
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with...
abcellera biologicsincstocksaxo
https://www.businesswire.com/news/home/20250516112255/en/AbCellera-Receives-Authorization-from-Health-Canada-to-Initiate-the-Phase-1-Clinical-Trial-of-ABCL635-for-Vasomotor-Symptoms-Due-to-Menopause
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of...
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
phase 1 clinical trial
https://www.biospace.com/abcellera-reports-q3-2023-business-results
AbCellera Reports Q3 2023 Business Results - BioSpace
Nov 2, 2023 - AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2023.
q3 2023business resultsabcellerareports
https://investingnews.com/abcellera-to-report-first-quarter-2026-financial-results-on-may-11-2026/
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 | INN
Apr 1, 2026 - AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m....
first quarter 2026
https://www.biospace.com/abcellera-announces-changes-to-its-board-of-directors
AbCellera Announces Changes to Its Board of Directors - BioSpace
Dec 7, 2021 - AbCellera (Nasdaq: ABCL), today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the...
board of directorsabcelleraannounceschanges
https://www.fiercebiotech.com/keyword/abcellera
AbCellera | Fierce Biotech
abcellerafiercebiotech
https://www.finder.com/ca/stock-trading/buy-abcellera-biologics-stock
Abcellera Biologics Inc Stock (ABCL): Price, How to Buy & More | Finder Canada
Sep 7, 2025 - : Find out how to buy Abcellera Biologics Inc (NASDAQ: ABCL) stock in Canada. Plus, see a detailed analysis of ABCL's stock price, chart and performance.
how to buyabcellera biologics
https://www.businesswire.com/news/home/20201210006243/en/AbCellera-Announces-Pricing-of-Initial-Public-Offering
AbCellera Announces Pricing of Initial Public Offering
AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.
abcelleraannouncespricinginitialpublic
https://theorg.com/org/abcellera?person=graham-craig
AbCellera | The Org
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to...
abcellera
https://www.biospace.com/abcellera-announces-two-t-cell-engager-presentations-at-sitc-2023
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 - BioSpace
Sep 27, 2023 - AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC)...
t cell engagerabcelleraannouncestwo
https://investingnews.com/abcellera-to-participate-at-upcoming-investor-conferences-in-november-and-december-2025/
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 | INN
Oct 7, 2025 - AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium,...
https://investingnews.com/abcellera-to-report-third-quarter-2025-financial-results-on-november-6-2025/
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 | INN
Sep 29, 2025 - AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00...
2025 financial resultsthird quarter
https://www.macrotrends.net/stocks/charts/ABCL/abcellera-biologics/gross-margin
AbCellera Biologics Gross Margin 2019-2025 | ABCL | MacroTrends
Current and historical gross margin for AbCellera Biologics (ABCL) over the last 10 years. The current gross profit margin for AbCellera Biologics as of...
abcellera biologicsgross margin20192025abcl
https://stockanalysis.com/stocks/abcl/employees/
AbCellera Biologics (ABCL) Number of Employees
Current and historical number of employees for AbCellera Biologics (ABCL) with related statistics, a chart and a data table.
abcellera biologicsabclnumberemployees
https://investingnews.com/abcellera-announces-first-patients-dosed-in-phase-2-portion-of-its-phase-1-2-clinical-trial-of-abcl635-for-the-treatment-of-vasomotor-symptoms-due-to-menopause/
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of...
Jan 12, 2026 - AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635....
https://capital.com/en-eu/markets/shares/abcellera-biologics-inc-share-price
AbCellera Biologics Inc (ABCL) Stock Price Quote Today & Current Price Chart | Capital.com EU
https://investingnews.com/abcellera-doses-first-participants-in-a-phase-1-clinical-trial-of-abcl575/
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 | INN
Sep 9, 2025 - ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis AbCellera...
phase 1 clinical trial